Shin Yasui, Keiichi Fujiwara, Osamu Yokosuka. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » AdultAntiviral Agents/adverse effectsAntiviral Agents/therapeutic useDrug Therapy, CombinationFemaleHepatitis C, Chronic/drug therapyHepatitis, Autoimmune/complicationsHepatitis, Autoimmune/etiologyHumansInterferon alpha-2Interferon-alpha/adverse effectsInterferon-alpha/therapeutic useLiver Failure, Acute/etiologyLiver Failure, Acute/pathologyLiver Failure, Acute/surgeryLiver TransplantationPolyethylene Glycols/adverse effectsPolyethylene Glycols/therapeutic useRecombinant Proteins/adverse effectsRecombinant Proteins/therapeutic useRibavirin/therapeutic use
Substances: See more » Antiviral AgentsInterferon alpha-2Interferon-alphaRecombinant ProteinsPolyethylene GlycolsRibavirinpeginterferon alfa-2b
Year: 2011 PMID: 21435960 DOI: 10.1016/j.dld.2011.02.014
Source DB: PubMed Journal: Dig Liver Dis ISSN: 1590-8658 Impact factor: 4.088